PARSEQ LAB
Desconocido
LungCARD: Blood test for clinical therapy guidance of non small cell lung cancer patients
PARSEQ LAB CO LTD
participó en un
H2020:
H2020-MSCA-RISE-2016
Lung cancer is the most common cancer worldwide. NSCLC alone make up about 75% of all lung cancers and most hospitals currently test all NSC...
2016-12-02 - 2022-10-31 | Financiado
2016-12-02 - 2022-10-31 | Financiado
* No se disponen de datos de la empresa actual.